I am a clinical associate professor in the Department of Human Oncology. My previous background as medical director of radiation oncology of a large, regional, NCI-funded Community Clinical Oncology Program (CCOP) is a little different than that of many clinicians. Our program’s goal was to tap into the latest high-level clinical research and technology while providing continuous and rapid clinical advancements as they arose to offer the most advanced, proven care available. With great pride, I serve in the DHO as part of this leading UW cancer program, which provides this kind of research and experience the world looks to for advancements.
The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better. One recent advancement that I employ is the use of a natural body substance, hyaluronic acid (SpaceOar gel), as a temporary barrier in select individuals to separate the rectum from high dose regions of the prostate.
In addition to staffing the UW Health East Radiation Oncology Clinic, which has a new state-of-the-art linear accelerator, I treat people with all types of cancer and have the pleasure of interacting with and training our physician and physics residents, particularly in the area of prostate brachytherapy. We need clinicians to become excellent providers of prostate brachytherapy, especially since the number of brachytherapy practitioners has fallen. As of 2017, the American Society for Clinical Oncology endorsed standard guidelines recommending consideration of brachytherapy treatment for prostate cancer in anyone with more than low-risk disease.
We continue always to explore and provide the highest level of care to our patients.
Resident, Medical College of Wisconsin Affiliated Hospitals, Radiation Oncology (1991)
Intern, Internship, Medical College of Wisconsin Affiliated, (1988)
MD, Medical College of Wisconsin, Medicine (1987)
BS, University of Wisconsin–Milwaukee, Zoology (1983)
Clinical Associate Professor, Human Oncology (2014-pres.)
Visiting Associate Professor, Human Oncology (2013-2014)
Selected Honors and Awards
Living Our Mission Award, St. Vincent Hospital (2003)
American Cancer Society Clinical Oncology Fellowship Award (1990–1991)
ASTRO Resident Essay Award Research (1990)
Boards, Advisory Committees and Professional Organizations
American Brachytherapy Society (2007–pres.)
American Society of Clinical Oncology (2000–pres.)
American Society for Therapeutic Radiology and Oncology (1988–pres.)
UW Health East Clinic
UW14083 Phase I/II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning
Dosimetric parameters in partial breast irradiation through brachytherapy. Med Dosim
Gloi A, McCourt S, Buchanan R, Goetller A, Zuge C, Balzoa P, Cooley G
2009; 34 (3): 207-13
The objective of this work is to evaluate biological models and dose homogeneity in a new partial breast irradiation method, the MammoSite RTS. The study is based on 11 patients who received the therapy. For each patient, we determined the dose volume distribution delivered to the breast. Based on these data, we estimate some important biological parameters. Eleven patients with early-stage, invasive, ductal breast cancer were treated using MammoSite RTS brachytherapy, which delivers radiation through a balloon placed in the lumpectomy bed. The radiation was provided by an Iridium-192 source, and 340 cGy were delivered per fraction twice daily. We calculated some commonly used dosimetric parameters, and evaluated the biological parameters tumor control probability (TCP) and normal tissue complication probability (NTCP). We also looked for correlations among these parameters. The average equivalent uniform dose (EUD), NTCP, and TCP were 43.66 Gy, 47.95%, and 91.78%, respectively. The coefficient of variation (CV) among the patients was very low for all 3 parameters. Two dose homogeneity indices (DHI and the S-index) are strongly correlated (r = -0.815). The area under the dose-volume histogram (DVH) and the treatment volume (TXV) also showed a strong correlation (r = 0.995, p < 0.0001). A simplified logit Poisson-EUD model is suitable for determining NTCP and TCP. Other factors such as the area under the DVH and dose homogeneity indices are also useful in planning radiotherapy treatments for early breast cancer.View details for PubMedID 19647630
A Bland-Altman analysis of the bias between computed tomography and ultrasound prostate volume measurements. Med Dosim
Gloi A, McCourt S, Zuge C, Goettler A, Schlise S, Cooley G
2008; 33 (3): 234-8
This study assesses the agreement between computed tomography (CT) measurements of prostate volume and those obtained by ultrasound (US), a well-established non-invasive technique. Twenty-six patients aged between 58 and 74 years were evaluated for prostate seed implant therapy using both CT and US measurements. The level of agreement between these 2 methods, which were strongly correlated (R2 = 0.828; p < 0.0001), was determined through Bland-Altman analysis. The mean prostate volume (+/- one standard deviation) of the sample was 31.8 +/- 10.5 cc for the CT method and 27.0 +/- 8.2 cc for the US method. The prostate volumes obtained by CT were, on average, 17% larger than the corresponding volumes determined by US. The average bias between the 2 imaging methods is 4.80 cc or 15%, which is significantly larger than the clinically acceptable margin of 10%.View details for PubMedID 18674689
Gregory Cooley, MD600 Highland Avenue, K4/B100,
Madison, WI 53792